Review
Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006
1 Drugs for Neglected Diseases Initiative (DNDi), 1 Place St Gervais, Geneva CH 1201, Switzerland
2 Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, 79 Taleghani Avenue, Tehran 14166, Iran
3 Centre Médical de l'Institut Pasteur, 28 rue du Docteur Roux, Cedex 15, Paris 75724, France
4 Dept Parasitology and Mycology, Institut Pasteur, 25 Rue du Docteur Roux, Cedex 15, Paris 75724, France
Kinetoplastid Biology and Disease 2007, 6:3 doi:10.1186/1475-9292-6-3
Published: 24 April 2007Additional files
Additional File 1:
Product Profile for CL treatment. What characteristics should an ideal product have for treatment of CL and what is the minimum requirement for a product to be introduced for control of CL, with emphasis first on ACL and secondly of CL latin America caused by L. braziliensis.
Format: XLS Size: 37KB Download file
This file can be viewed with: Microsoft Excel Viewer
